Hypothesis

Centrosome amplification in aged somatic cells is not merely a by‑product of damage but an active signal that modulates the germline stem cell niche to limit reproductive output, thereby enforcing generational turnover. According to this view, supernumerary centrosomes trigger a p53‑dependent senescence program that releases a specific subset of senescence‑associated secretory phenotype (SASP) factors—particularly IGF‑binding proteins and Wnt antagonists—into the circulation. These factors travel to the gonad where they suppress germline stem cell proliferation, reducing fecundity in older individuals. Evolution would retain this mechanism because it speeds up allele turnover and enhances population adaptability without requiring lethal pathology.

Mechanistic Reasoning

1. Centrosome‑p53‑SASP link – In late‑passage fibroblasts, loss of γ‑tubulin and pericentrin leads to centrosome fragmentation, which recruits p53 to the amplified centrosomes 6. p53 then transcriptionally activates a restricted SASP profile enriched for IGFBP‑5 and SFRP2, proteins known to inhibit germline stem cell activity 3.

2. Systemic communication – Extracellular vesicles shed from senescent centrosome‑amplified cells carry these SASP proteins to the gonadal niche, where they activate downstream pathways (e.g., reduced AKT signaling in germline stem cells) that induce quiescence or apoptosis.

3. Feedback to somatic aging – Reduced germline signaling lowers circulating gonadotropins, which in turn diminishes gonadal steroid production, reinforcing somatic senescence via altered metabolic homeostasis—a loop that couples reproductive decline with organismal aging.

Testable Predictions

• Genetic suppression: Conditional knockout of pericentrin in liver or muscle of aged mice will reduce centrosome amplification, lower IGFBP‑5/SFRP2 levels in serum, and extend lifespan without increasing tumor incidence. If the hypothesis is false, lifespan will not change despite reduced centrosome numbers.

• SASP neutralization: Administration of neutralizing antibodies against IGFBP‑5 or SFRP2 in aged animals should rescue germline stem cell proliferation (measured by BrdU incorporation in testis/ovary) and increase litter size, while leaving somatic senescence markers (p16, SA‑β‑gal) unchanged.

• Gain‑of‑function: Overexpressing pericentrin‑destabilizing peptides in young mice to induce centrosome amplification will prematurely elevate serum IGFBP‑5/SFRP2, decrease germline stem cell activity, and shorten reproductive span, even if overall longevity is unaffected.

• Population competition: In mixed‑age Drosophila populations, flies with genetically dampened centrosome amplification (via pericentrin RNAi) will show higher individual longevity but lower competitive advantage over generations compared with wild‑type flies, supporting a group‑selection benefit.

Falsifiability

If any of the above interventions fail to produce the predicted directional changes—e.g., reducing centrosome amplification does not alter circulating IGFBP‑5/SFRP2 or germline activity, or neutralizing those factors does not improve fecundity—the hypothesis would be refuted, suggesting centrosome amplification acts solely as a cell‑intrinsic timer without systemic reproductive regulation.

Implications

Viewing centrosome amplification as a programmed signal reframes longevity medicine: rather than bluntly blocking senescence, therapies could fine‑tune the SASP‑germline axis to extend healthspan while preserving the evolutionary advantage of generational turnover.